Member Info for RNmyS

Case in point: https://twitter.com/OmegaDiagnostic/status/1390297622519291908?s=20

You call me a fool and berate me for bringing up the case for an Avacta NASDAQ listing in the future, yet Avacta continue to make strides towards a potential listing.

Thanks Vostick, much appreciated

Vostick, do you have a link to the leaflet? Thanks

Thank you for sharing this, that's a great bit of research!

@Computer909, just to be clear, the Avacta test also has a read time of 10mins for most viral loads (20mins for very small viral loads), "The test works perfectly well with a 10min read..."
Source: https://youtu.be/QKc7VuKzP1Y?t=893

Both tests have performed very well, and it is very good to see that Mologic were proactive in getting an independent study done in such a timely manner. I am sure both tests will sell very well.

Well Mologic have given their own test to ODX who are going to be selling it and branding it as their own, so IMO the likelihood is that Avacta will be taking most of what GAD has to offer.

I've seen this shared around a fair bit:

ODX Capacity: 8m / month (by 1st May)
ABDX Capacity: 12m / month (end of 2021)
Medusa: 50m / month (Regarding their RSPT: "Medusa 19 is planning to ramp up production to 50m tests each month at its manufacturing site in the Wirral.")
GAD / Mologic: 20m / month (conservative est)

Screen-grab: https://ibb.co/NtkK1pw

Stupid oversight here, thanks for noting.

Hi All,

I've seen a lot of people discussing the recent results of the VISITECT test, and subsequent ODX RNS, which states: "The VISITECT® COVID-19 Antigen test has demonstrated excellent performance characteristics through independent multi-centre validation studies. The test has sensitivity of 98.4% on samples with a cycle threshold (Ct) of < 20 (85% overall sensitivity on samples with Ct values ranging from 9.8 to 43) and specificity of 97.8%."

While they fail to provide a breakdown of the results in that RNS, it's worth noting the performance data for the test has been available for some time: https://mologic.co.uk/wp-content/uploads/2021/03/COVID-19-rapid-antigen-test-February-16-2021-v1.pdf

In particular, its worth noting that the VISITECT test has a sensitivity of 90.2% at CT <25, which is just barely in the governments required 90% range (AffiDX has a sensitivity of 100% at CT <27 FYI).

The biggest worry for the Mologic VISITECT test, is the low ease of use score: 57/100, this is likely due to the tests Nasopharyngeal collection method (brain tickler) which is more complicated versus our simpler Anterior Nasal collection method.

It is good to see their test getting independently verified and I'm sure we will see the same from our own soon.

2.64

Will Paul do another release after market close today..? (If of course there is an article in the works)

I did ask about the Indian strain during the recent presentation, however, as with most other questions it seems the interviewer decided to only ask Alastair questions which had already been answered, hopefully we will know soon enough. I presume they’re working on it though as they’re placing some focus on “low to middle income counties”

Thanks for sharing martnotsosmart, those comments made by Deeks are very irritating to read.

He compares our test to the Innova test even though they only validated on at CT <26 using nasopharyngeal sampling (AffiDX had 100% sens within this range using anterior nasal).

Claimed we cannot tell what is and is not infectious, even though this was clearly explained and illustrated in a reply to his comment (and by Alastair Smith during the presentation). Then went on further to claim, "‘tests of infectiousness’ more marketing than science"

What a Twat.

Motley Fool, i.e. the people that referred to Avacta as a "crypto currency minor", are a waste of space. Their research is damn basic and poorly done.

.

Here's a full screen-grab: https://ibb.co/f05mCYV

:)

Positive reaction to the Mologic Tweet? Either way, good to see.

Deeks has an agenda, found this thread where he shared his thoughts on our LTF here: https://twitter.com/veekci/status/1385898147453489152?s=20

TL;DR:
- Deeks compares our LTF to Innova's and says we can't trust the results
He never considers the different CT values used to validate the tests (<26 for Innova, <31 for Avacta).
- Deeks questions how we distinguish what is / is not infectious and claims it's all just marketing...

Give it a read, clear bias being shown by him.